FDA grants priority review and EMA accepts regulatory submission for Pfizer’s abrocitinib

This article was originally published here

The FDA is expected to make a decision in April 2021. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for abrocitinib in the

The post FDA grants priority review and EMA accepts regulatory submission for Pfizer’s abrocitinib appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply